Top Page
Biogen
(NASDAQ:BIIB)
Biogen (BIIB) vs. SPDR S&P 500 ETF (SPY)
Biogen Business Overview & Revenue Model
Biogen Key Performance Indicators (KPIs)
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to enhance Biogen's overall performance.
Main Street DataBiogen Earnings Call Summary
Biogen Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.99B | 9.68B | 9.84B | 10.17B | 10.98B | 13.44B |
| Gross Profit | 7.00B | 7.37B | 7.30B | 7.90B | 8.87B | 11.64B |
| EBITDA | 3.49B | 3.00B | 2.38B | 3.54B | 3.92B | 5.11B |
| Net Income | 1.61B | 1.63B | 1.16B | 3.05B | 1.56B | 4.00B |
Balance Sheet | ||||||
| Total Assets | 29.21B | 28.05B | 26.84B | 24.55B | 23.88B | 24.62B |
| Cash, Cash Equivalents and Short-Term Investments | 3.96B | 2.38B | 1.05B | 4.89B | 3.80B | 2.61B |
| Total Debt | 6.59B | 6.63B | 7.34B | 6.61B | 7.60B | 7.83B |
| Total Liabilities | 11.00B | 11.33B | 12.05B | 11.17B | 12.92B | 13.93B |
| Stockholders Equity | 18.21B | 16.72B | 14.80B | 13.40B | 10.90B | 10.70B |
Cash Flow | ||||||
| Free Cash Flow | 2.28B | 2.52B | 1.24B | 1.14B | 3.38B | 3.81B |
| Operating Cash Flow | 2.45B | 2.88B | 1.55B | 1.38B | 3.64B | 4.23B |
| Investing Cash Flow | -158.00M | -799.20M | -4.09B | 1.59B | -563.70M | -608.60M |
| Financing Cash Flow | -157.00M | -683.50M | 137.00M | -1.76B | -2.09B | -5.27B |
Biogen Technical Analysis
Biogen Risk Analysis
Biogen Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $92.67B | 13.04 | 35.62% | 3.59% | 5.97% | 128.66% | |
| ― | $148.64B | 18.57 | 40.62% | 2.62% | 2.71% | 6407.19% | |
| ― | $22.22B | 13.81 | 9.31% | ― | 5.00% | -1.03% | |
| ― | $160.66B | 24.42 | 99.14% | 3.15% | 13.10% | 110.67% | |
| ― | $93.69B | 15.54 | 33.84% | 5.39% | 1.26% | ― | |
| ― | $374.44B | 159.25 | ― | 3.01% | 7.40% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Biogen Corporate Events
Biogen Inc. is a leading biotechnology company that focuses on developing innovative therapies for neurological and rare diseases, with a strong emphasis on leveraging scientific advancements to improve patient outcomes. In its latest earnings report, Biogen Inc. announced a robust financial performance for the third quarter of 2025, with total revenue reaching $2.5 billion, marking a 3% increase compared to the previous year. The company’s GAAP diluted earnings per share (EPS) rose by 19% to $3.17, while the non-GAAP diluted EPS increased by 18% to $4.81.
Biogen Inc. is currently conducting a clinical study titled An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]. The study aims to assess the effects and safety of felzartamab infusions in adults with PMN, a condition where autoantibodies damage the kidney’s filtering units, leading to potential kidney failure. The primary objective is to determine how many participants achieve a complete response after 104 weeks of treatment, with secondary objectives including the time to disease progression and the development of antibodies against felzartamab.
Study Overview: Biogen Inc. is conducting a Phase 3 trial titled A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR). The study aims to assess the effectiveness of felzartamab compared to a placebo in treating patients with late active or chronic active AMR, a significant complication in kidney transplant recipients.
Biogen Inc. is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE) who have completed previous treatment periods in parent studies. The primary focus is on understanding adverse events and the drug’s impact on SLE symptoms.
Biogen Inc. is conducting a Phase 3 study titled ‘A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus.’ The study aims to evaluate the long-term safety and efficacy of litifilimab in adults with active subacute or chronic cutaneous lupus erythematosus, particularly those unresponsive or intolerant to antimalarial therapy. This research is significant as it seeks to provide a viable treatment option for patients with limited alternatives.
Biogen Inc. is conducting a clinical study titled A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI). The study aims to assess the effects of felzartamab on kidney inflammation in patients who have undergone kidney transplants and developed MVI, a condition that can lead to serious kidney issues. The primary objective is to determine how many participants show no signs of active inflammation after 24 weeks of treatment.
Biogen Inc. is conducting a study titled Pregnancy Outcomes in Women Exposed to Diroximel Fumarate, aiming to assess the safety of Diroximel Fumarate (VUMERITY®) in pregnant women with multiple sclerosis (MS) and the health of their babies. The study’s primary goal is to gather data on major congenital malformations and other pregnancy outcomes in three groups: those exposed to Diroximel Fumarate, those on other MS drugs, and those on no MS drugs during pregnancy.
Biogen Inc. is conducting a 2-part clinical study titled ‘A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST).’ The study aims to assess the efficacy and safety of litifilimab (BIIB059) in reducing skin disease activity in participants with cutaneous lupus erythematosus (CLE) who have not responded to antimalarial therapy.
Biogen Inc. is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effects of felzartamab on proteinuria in adults with Immunoglobulin A Nephropathy (IgAN), a kidney condition. The primary objective is to assess changes in protein levels in urine over 36 weeks, alongside evaluating the drug’s safety and kidney filtration effects.
Biogen Inc. is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care. The study aims to assess the safety and efficacy of litifilimab in reducing disease activity in adults with systemic lupus erythematosus (SLE) who are already on standard treatments. The primary goal is to determine how many participants show symptom improvement after 52 weeks of treatment.
Biogen Inc. is conducting a clinical study titled An Open-Label, Phase 1, Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Pharmacodynamics, and Efficacy of Omaveloxolone in Participants ≥2 to <16 Years of Age With Friedreich's Ataxia. The study aims to understand how the drug BIIB141, also known as omaveloxolone, is processed in the bodies of children and teens aged 2 to 15 with Friedreich's Ataxia, a condition for which the drug is already approved for those 16 and older.
Biogen Inc. is currently conducting a study titled ‘Spinraza (Nusinersen) SMA Pregnancy Exposure Study Within Existing SMA Registries.’ The study aims to understand the effects of the drug nusinersen, known as Spinraza®, on pregnant participants with spinal muscular atrophy (SMA) and the health of their babies. This research is significant as it seeks to fill the knowledge gap regarding the impact of nusinersen on pregnancy outcomes and infant health in SMA patients.
Biogen Inc., in collaboration with Alcyone Therapeutics, is conducting a clinical study titled ‘Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and Delivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar Puncture Trial (PIERRE)’. The study aims to evaluate the safety and performance of the ThecaFlex DRx™ System in delivering nusinersen to patients with spinal muscular atrophy (SMA) who are resistant to lumbar puncture. This study is significant as it seeks to improve treatment delivery for SMA patients facing challenges with traditional methods.
Biogen Inc. is conducting a Phase 3 clinical study titled A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study (Part 1) and Open-Label Extension (Part 2) to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich’s Ataxia Aged 2 to < 16 Years. The study aims to assess the effects and long-term safety of BIIB141, also known as omaveloxolone, in children and teens with Friedreich's Ataxia (FA) aged 2 to 15 years. This research is significant as the drug is currently approved for those aged 16 and older, and this study could expand its use to a younger demographic.
Biogen Inc. is conducting a Phase 1 clinical trial to evaluate the safety and processing of BIIB142 in healthy adults aged 18 to 55. Officially titled ‘A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB142 in Healthy Adults,’ the study aims to determine the occurrence of adverse events and how the body processes the drug. This study is significant as it marks the first time BIIB142 is being tested in humans.
Biogen Inc. is conducting a study titled ‘An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx™ System (PIERRE-PK).’ The study aims to understand how nusinersen, a treatment for spinal muscular atrophy (SMA), is processed by the body when delivered through the ThecaFlex DRx™ System compared to traditional lumbar puncture. This research is significant as it could improve treatment delivery methods for SMA patients.
Biogen Inc. is currently conducting a study titled A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants. The study aims to understand how the body processes litifilimab when delivered subcutaneously through different devices, focusing on pharmacokinetic comparability.
Biogen Inc. is currently recruiting participants for a study titled ‘Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry.’ The study aims to assess the risk of major congenital malformations in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) during pregnancy. It also compares pregnancy outcomes with women exposed to other disease-modifying therapies (DMTs) or unexposed to any DMTs.
Biogen Inc. is currently conducting a study titled ‘Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting.’ The study aims to understand how zuranolone affects postpartum depression (PPD) symptoms in individuals who have taken the drug within a year after pregnancy. This research is significant as it seeks to provide insights into the real-world effectiveness of zuranolone, a treatment option for PPD, which can severely impact new parents’ mental health.
Biogen Inc. and Denali Therapeutics have launched a Phase 2a study titled ‘A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD).’ The study aims to assess the safety, tolerability, and pharmacodynamic effects of BIIB122 in individuals with LRRK2-PD, a form of Parkinson’s Disease linked to a genetic variant that increases LRRK2 kinase activity.
Biogen Inc. is conducting a study titled A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications, and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation. The study aims to evaluate the safety of BIIB141 (Omaveloxolone) for individuals with Friedrich’s Ataxia who took the drug during pregnancy and/or breastfeeding, focusing on potential birth defects and maternal health complications.
Biogen Inc. is conducting a clinical study titled ‘A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis.’ The study aims to assess the safety of BIIB091, both alone and in combination with Diroximel Fumarate (DRF), in adults with relapsing forms of Multiple Sclerosis (MS). This research is significant as it seeks to understand the safety profile and impact on brain inflammation of these treatments, potentially offering new therapeutic options for MS patients.
Study Overview: Biogen Inc. is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care. The study aims to assess the efficacy and safety of litifilimab in reducing disease activity in adults with systemic lupus erythematosus (SLE) who are already on standard care medications.
Biogen Inc. is conducting a study titled An Observational, Multinational, Post-Marketing Registry of Omaveloxolone-Treated Patients With Friedreich’s Ataxia to evaluate the long-term safety of BIIB141, known as omaveloxolone or SKYCLARYS®. The study aims to gather safety data on patients with Friedreich’s Ataxia (FA) who are prescribed this drug by their doctors, focusing on serious adverse events and those related to heart failure or liver damage.
Biogen Inc. is conducting a study titled A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants. The study aims to understand how the body processes litifilimab when administered under the skin using different devices, which could improve delivery methods for patients with limited dexterity or needle phobia.
Biogen Inc. (BIIB) is currently conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL). The study aims to evaluate the effects of felzartamab on proteinuria in patients with Immunoglobulin A Nephropathy (IgAN), a kidney condition that leads to protein in urine due to kidney damage.
Biogen Inc. (BIIB) is conducting a Phase 3 long-term extension study titled ‘A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus.’ The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE), focusing on adverse events, symptom control, and quality of life.
Biogen Inc. is currently conducting a significant Phase 3 clinical trial titled ‘A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)’. The primary objective of this study is to assess the efficacy of felzartamab, a promising therapeutic agent, in treating kidney transplant recipients experiencing late antibody-mediated rejection.
Biogen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to assess the effects of felzartamab on proteinuria and kidney function in adults with Immunoglobulin A Nephropathy (IgAN), a condition characterized by protein in the urine due to kidney damage.
Biogen Inc. (BIIB) is conducting a study titled A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants. The study aims to evaluate how the body processes litifilimab when administered under the skin using three different devices, focusing on pharmacokinetic comparability, safety, and tolerability.
Biogen Inc. has initiated a Phase 3 clinical trial titled A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR). The study aims to assess the effectiveness of felzartamab, a drug intended to treat late active or chronic active antibody-mediated rejection in kidney transplant patients, compared to a placebo.
Biogen Inc. (BIIB) is conducting a significant clinical study titled A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich’s Ataxia Aged 2 to < 16 Years. The study aims to explore the effects and long-term safety of BIIB141, also known as omaveloxolone, in children and teens with Friedreich's Ataxia (FA), a condition for which the drug is currently approved only for individuals aged 16 and older.
Biogen Inc. (BIIB) is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab, a drug intended to manage symptoms of systemic lupus erythematosus (SLE) in adults who have completed previous treatment periods. This study is significant as it seeks to provide insights into the drug’s safety profile and its potential to improve patient outcomes over an extended period.
Biogen Inc. (BIIB) is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effects of felzartamab on proteinuria in patients with immunoglobulin A nephropathy (IgAN), a condition that causes protein leakage into urine due to kidney damage. The significance lies in potentially improving kidney function and patient outcomes.
Biogen Inc. is currently recruiting participants for a Phase 3 trial titled A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR). The study aims to assess the effectiveness of felzartamab, a drug administered via intravenous infusion, in treating kidney transplant recipients with late active or chronic active AMR, compared to a placebo.
Biogen Inc. (BIIB) is currently recruiting participants for a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL). The study aims to evaluate the effects of felzartamab on proteinuria in adults with Immunoglobulin A nephropathy (IgAN), a condition characterized by kidney damage leading to protein in the urine. The primary objective is to assess the change in protein levels in urine over 36 weeks, alongside evaluating kidney function and the safety profile of felzartamab.
Biogen Inc. (BIIB) is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE), focusing on adverse events and symptom control.
Biogen Inc. (BIIB) is conducting a Phase 3 clinical study titled A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus. The study aims to evaluate the long-term safety and efficacy of litifilimab in adults with active subacute or chronic cutaneous lupus erythematosus (CLE), particularly those unresponsive or intolerant to antimalarial therapy.
Biogen Inc. (BIIB) is conducting the PIERRE-PK study to evaluate how the body processes the drug nusinersen when administered through the ThecaFlex DRx™ System compared to the traditional lumbar puncture method. This study aims to determine the highest concentration of nusinersen in the blood post-dosing and its presence over a 24-hour period. The ThecaFlex DRx™ System, developed by Alcyone Therapeutics, Inc., is an investigational implantable device designed to improve drug delivery in patients with spinal muscular atrophy (SMA).
Biogen Inc. (BIIB), in collaboration with Alcyone Therapeutics, is conducting a pivotal clinical study titled ‘Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and Delivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar Puncture Trial (PIERRE)’. The study aims to evaluate the safety and efficacy of the ThecaFlex DRx™ System in delivering nusinersen to SMA patients, potentially supporting a Pre-Market Approval (PMA) application.
Biogen Inc. (BIIB) is currently conducting a clinical study titled ‘A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)’. The study aims to assess the efficacy and safety of litifilimab (BIIB059) in reducing skin disease activity in participants with cutaneous lupus erythematosus (CLE) who have not responded to antimalarial therapy.
Biogen Inc. Reports Strong Quarter with Positive Earnings Call Sentiment
Biogen Inc. has launched a new clinical study titled ‘Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry.’ The study aims to assess the risk of major congenital malformations in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) during pregnancy. It also compares these outcomes with those in women exposed to other disease-modifying therapies (DMTs) or none at all, as well as with women without MS.
Biogen Inc. has initiated a Phase 3 clinical trial titled ‘A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)’. The study aims to assess the effectiveness of felzartamab compared to a placebo in treating late active or chronic active AMR in kidney transplant recipients, a significant concern in transplant medicine.
Biogen Inc. is a leading biotechnology company focused on developing innovative therapies for neurological and rare diseases, leveraging its deep understanding of human biology to deliver transformative medicines.
Biogen Inc. is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab, focusing on its impact on the symptoms and disease activity of systemic lupus erythematosus (SLE) in adults already on standard care medications. This research is significant as it seeks to provide insights into the long-term treatment potential of litifilimab for SLE.